Clin2
NCT06150365Possibly a fitRecruiting

Personalized T-cell therapy for advanced solid tumors (KSX01-TCRT)

Refractory Solid TumorsRelapsed Solid Tumors

Part of Cancer clinical trials.

This study tests a personalized treatment made from your own immune cells (T cells) that are re-engineered to recognize and attack your specific tumor. It is for people with advanced solid tumors that have not responded to other treatments. If you qualify, you will have a blood draw and a tumor sample collected to create your own custom T cell therapy.

Summary written for real people, not researchers, by Clin2.

Phase
Early Phase 1
Enrollment
12 people
Ages
18 years to 70 years
Study type
Interventional

Who can take part

  • You have an advanced solid tumor that has not been controlled by standard treatments or has no standard treatment available.
  • You are between 18 and 70 years old and your doctor expects you to live more than 6 months.
  • You have adequate organ function (blood counts, liver, kidneys) and are able to undergo a blood collection procedure.
  • Your tumor cells have a specific immune marker (HLA-I) that can be found by testing, and a tumor tissue sample is available to create the personalized T cells.
  • You have not received more than two prior chemotherapy regimens for advanced disease, and you are not pregnant or breastfeeding.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05811975Recruiting· Early Phase 1
Personalized T-cell therapy for advanced solid tumors

This early-phase study tests a personalized treatment made from your own immune cells to attack solid tumors that have not responded to standard care. If you qualify, the team will collect blood cells, prepare the therapy, and give it back to you with close monitoring for safety and early signs of benefit.

Nanning, Guangxi
NCT05539833Recruiting· Early Phase 1
TCR-T cell therapy for HLA-A2 positive solid tumors

This early-phase study tests a personalized immune-cell treatment (TCR-T cells) made from your own immune cells. You may qualify if you have a solid tumor that shows a specific target on tumor cells and your body type (HLA-A2) matches what the therapy needs.

Nanning, Guangxi
NCT07275853Not yet recruiting· Phase 1
Personalized immune cell therapy for advanced solid tumors

This trial tests a personalized cell therapy that uses your own immune cells (T-cells) specially modified to target your tumor. It is for people with advanced solid tumors who have run out of standard treatment options.

Beijing
NCT05580796Recruiting· Early Phase 1
TCR-T cell therapy for HLA-A*02 positive solid tumors

This trial tests a personalized immune-cell treatment made from your own blood to target certain solid tumors. You may be eligible if your tumor has a specific protein pattern and you have tried standard treatments without success.

Beijing, Beijing Municipality
NCT06397963Recruiting
Personalized immune cell therapy for advanced solid tumors

This study tests a new treatment using your body's own immune cells (called tumor-infiltrating lymphocytes) that are taken from your tumor, grown in a lab, and then put back into you. It's for people with advanced solid tumors who have run out of standard options.

Beijing, Beijing Municipality
NCT07482319Not yet recruiting· Phase 1
Testing a new cell treatment for advanced solid tumors

This trial tests an injection of your own immune cells (tumor-infiltrating lymphocytes) to see if they can fight advanced solid tumors like stomach or lung cancer. Doctors will remove one of your tumors, grow the immune cells from it, and then give them back to you.

Beijing

Hear when a new Refractory Solid Tumors trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.